Jana Rathouska, PharmDr., Ph.D.

Born: August 14, 1985, Chomutov, Czech Republic.

 

Education, Academic and Scientific Degrees:

2014 – Assistant professor at Department of Biological and Medical Sciences (FParm HK), 2014 – Ph.D. in Pharmacology (FPharm HK), 2014 – PharmDr. (FPharm HK), 2009 – MSc. in Pharmacy (FPharm HK).

Working Experience:

2014 – Assistant professor, 2012 – Research assistant (all appointments at Faculty of Pharmacy (FPharm HK), Department of Biological and Medical Sciences).

Research Interests

Experimental atherosclerosis, mouse models of atherosclerosis, endothelial dysfunction

Teaching

Since 2010 – teaching of seminars and practical classes of Microbiology (2010), Immunology (since 2010, since 2014 also in English), Morphology and Physiology (2011), Pathological Physiology (since 2011, since 2014 also in English) in Pharmacy students, since 2014 seminars of Pathology in Healthcare Bioanalytics students, since 2016 examiner of Pathology; supervisor of bachelor (3x), diploma (11x) and rigorous (3x) theses.

Memberships in Scientific Societies:

European Atherosclerosis Society since 2009, Czech Society for Atherosclerosis since 2010

Awards

2011 – Best original article of the year (1st place) awarded by Czech Society for Atherosclerosis (co-author) – “Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice” (Circulation Journal)

2014 - Best original article of the year (1st place) awarded by Czech Society for Atherosclerosis (1st author) – “Endoglin is not expressed with cell adhesion molecules in aorta during atherogenesis in apoE-deficient mice” (Histology and Histopathology)

Selected Lectures at Conferences

– 19th Congress of Czech Society for Atherosclerosis, Spindleruv Mlyn (Czechia), 2015.

Peer Review

– Reviewer of 1 manuscript submitted into scientific journal with IF (JCPT)

– Reviewer of 1 grant application - Czech agency GA UK

– Bachelor/Diploma theses (14x/FaF), rigorous theses – (3x/FaF).

Grant Projects

As a principal investigator (1x): “Study of endoglin/Smad signaling cascade in different stages of atherogenesis and after statin treatment”

As a co-investigator: GA ČR (1x), GA UK (3x), UNCE (1x), PRVOUK (1x)

Publications and Citations (in total):

– Number of publications in WoS/Scopus: 15/16, all with IF

– Number of citations in WoS/Scopus – total 134/159, without self-citations 102/118.

– H-index in WoS/Scopus (with self-citations) = 7/8.

Summary of Publications (in last 5 years, 2012-2017):

in WoS/Scopus: 12/13, cumulative IF = 45.236, average IF = 3.48.

Summary of all publications

1.         Rathouska J, Fikrova P, Mrkvicova A, Blazickova K, Varejckova M, Dolezelova E, Nemeckova I, Vitverova B, Peslova L, Gallardo-Vara E, Pericacho M, Nachtigal P. High soluble endoglin levels do not induce changes in structural parameters of mouse heart. Heart Vessels. 2017 (IF=3.434)

2.         Varejckova M, Gallardo-Vara E, Vicen M, Vitverova B, Fikrova P, Dolezelova E, Rathouska J, Prasnicka A, Blazickova K, Micuda S, Bernabeu C, Nemeckova I, Nachtigal P. Soluble endoglin modulates the pro-inflammatory mediators nf-kappab and il-6 in cultured human endothelial cells. Life Sci. 2017;175:52-60 (IF=2.936)

3.         Jezkova K, Rathouska J, Nemeckova I, Fikrova P, Dolezelova E, Varejckova M, Vitverova B, Tysonova K, Serwadczak A, Buczek E, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P. High levels of soluble endoglin induce a proinflammatory and oxidative-stress phenotype associated with preserved no-dependent vasodilatation in aortas from mice fed a high-fat diet. J Vasc Res. 2016;53:149-162 (IF=1.759)

4.         Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and c-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016;15:344-353 (IF=8.961) (Q1)

5.         Sahebkar A, Rathouska J, Simental-Mendia LE, Nachtigal P. Statin therapy and plasma cortisol concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016;103:17-25 (IF=4.408) (Q1)

6.         Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243:383-388 (IF=3.942) (Q1)

7.         Zemankova L, Varejckova M, Dolezalova E, Fikrova P, Jezkova K, Rathouska J, Cerveny L, Botella LM, Bernabeu C, Nemeckova I, Nachtigal P. Atorvastatin-induced endothelial nitric oxide synthase expression in endothelial cells is mediated by endoglin. J Physiol Pharmacol. 2015;66:403-413 (IF=2.804)

8.         Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, Varejckova M, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P. High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta. PLoS One. 2015;10:e0119665 (IF=3.057) (Q1)

9.         Rathouska J, Jezkova K, Nemeckova I, Zemankova L, Varejckova M, Nachtigal P. Endoglin is not expressed with cell adhesion molecules in aorta during atherogenesis in apoe-deficient mice. Histol Histopathol. 2015;30:233-244 (IF=2.096)

10.       Rathouska J, Nemeckova I, Zemankova L, Strasky Z, Jezkova K, Varejckova M, Nachtigal P. Cell adhesion molecules and enos expression in aorta of normocholesterolemic mice with different predispositions to atherosclerosis. Heart Vessels. 2015;30:241-248 (IF=2.293)

11.       Strasky Z, Zemankova L, Nemeckova I, Rathouska J, Wong RJ, Muchova L, Subhanova I, Vanikova J, Vanova K, Vitek L, Nachtigal P. Spirulina platensis and phycocyanobilin activate atheroprotective heme oxygenase-1: A possible implication for atherogenesis. Food Funct. 2013;4:1586-1594 (IF=2.907) (Q1)

12.       Nachtigal P, Zemankova Vecerova L, Rathouska J, Strasky Z. The role of endoglin in atherosclerosis. Atherosclerosis. 2012;224:4-11 (IF=3.706) (Q1)

13.       Vecerova L, Strasky Z, Rathouska J, Slanarova M, Brcakova E, Micuda S, Nachtigal P. Activation of tgf-beta receptors and smad proteins by atorvastatin is related to reduced atherogenesis in apoe/ldlr double knockout mice. J Atheroscler Thromb. 2012;19:115-126 (IF=2.933)

14.       Strasky Z, Vecerova L, Rathouska J, Slanarova M, Brcakova E, Kudlackova Z, Andrys C, Micuda S, Nachtigal P. Cholesterol effects on endoglin and its downstream pathways in apoe/ldlr double knockout mice. Circ J. 2011;75:1747-1755 (IF=3.766) (Q1)

15.       Rathouska J, Vecerova L, Strasky Z, Slanarova M, Brcakova E, Mullerova Z, Andrys C, Micuda S, Nachtigal P. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res. 2011;64:53-59 (IF=4.436) (Q1)

16.       Zadak Z, Hyspler R, Ticha A, Hronek M, Fikrova P, Rathouska J, Hrnciarikova D, Stetina R. Antioxidants and vitamins in clinical conditions. Physiol Res. 2009;58 Suppl 1:S13-17 (IF=1.43)

© 2017 Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
Website information | Powered by Kentico